Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CES1 | P23141 | 2/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | MME | P08473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308893 | 0.88 | CES2 (0.47) | CES2CES1NR1I2HTR7ADAM17 | |
| Trifluoromethanesulfonic Acid SCHEMBL27525495 | 0.75 | NR1I2 (0.49) | CES2CES1NR1I2PTPN1 | |
| SCHEMBL13885099 | 0.73 | SHBG (0.47) | NR1I2 | |
| SCHEMBL8282339 | 0.72 | ALDH1A1 (0.33) | CES2CES1NR1I2HTR7 | |
| SCHEMBL19136180 | 0.72 | FAAH (0.38) | NR1I2 | |
| SCHEMBL25237882 | 0.72 | PARP1 (0.33) | CES2CES1NR1I2HTR7 | |
| SCHEMBL19137400 | 0.72 | KDM1A (0.33) | CES2CES1NR1I2HTR7 | |
| SCHEMBL13710896 | 0.72 | SLC6A2 (0.43) | DPP4DPP9DPP7 | |
| SCHEMBL13345093 | 0.72 | HTR7 (0.42) | CES2CES1NR1I2HTR7 | |
| SCHEMBL13710897 | 0.72 | SCN8A (0.36) | NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | BTG INTERNATIONAL LIMITED (GB) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289523-A1 | PYRROLO [3,2-E] [1,2,4] TRIAZOLO [1,5-A] PYRIMIDINES DERIVATIVES AS INHIBITORS OF MICROGLIA ACTIVATION | CX3CR1, CSF1R, PSEN1 | CES2 299/4885CES1 332/4885NR1I2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.